Measurement of carcinogen DNA adducts in blood has been used as a surrogate for the target lung tissue. We aimed to examine whether genetic polymorphisms in several metabolic pathway genes modify the relation between DNA adducts in target lung and blood. One hundred and thirty-five early-stage lung cancer patients from the Massachusetts General Hospital were studied. DNA adducts were measured by the 32 P-postlabeling assay in lung and blood mononuclear cells (MNCs) in a subset of 53 who had paired blood samples. Single-nucleotide polymorphisms (SNPs) were assessed in genes involved in phase II (GSTs, NAT2, EPHX and NQO1), DNA repair (ERCC1, ERCC2 and XRCC1) and DNA methylation (MTHFR C677T and A1298C) pathways. There was a significant correlation between DNA adduct levels in lung and blood within the different genotypes, with one exception. Significant modifications in adducts were found by variants in genes for phase II metabolism [NAT2 (1.51 for rapid versus 0.76 for slow, P 5 0.022)], DNA repair [ERCC1 C118T (P 5 0.014), ERCC2 (P 5 0.003) and XRCC1 (P 5 0.025)] and MTHFR [C677T (P 5 0.005) and A1298C (P 5 0.005)]. The relation between DNA adducts in blood MNCs and target lung tissue was significantly modified by the single-nucleotide polymorphisms in the three main pathways. Despite the relatively small sample size, our results suggest that genetic factors may need to be considered when assessing the association of DNA adducts using surrogate tissue in studies of lung cancer. Further studies are needed to better understand their role and the mechanisms.
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Introduction
DNA adducts in non-target tissue, used as a surrogate for the lung, have been used as biomarkers of lung cancer risk (1) . Although a strong correlation between DNA adducts levels in different tissues has been reported previously (2, 3) , suggesting reliability rather than validity, the predictive value of DNA adducts in surrogate tissue has been conflicting in terms of lung cancer risk (4) (5) (6) (7) (8) (9) . Among these studies, very few studies considered the genetic factors in the reported association (5, 8) , as summarized in Table I .
Genetic polymorphisms in three pathways: phase II [glutathione S-transferases (GSTs), N-acetyltransferase-2 (NAT2), encoding microsomal epoxide hydrolase (EPHX) and NAD(P)H quinone oxidoreductase 1 (NQO1)], DNA repair [excision repair cross complementation group 1 (ERCC1), excision repair cross complementation group 2 (ERCC2) and X-ray repair cross complementing group 1 (XRCC1)] and DNA methylation [methylenetetrahydrofolate reductase (MTHFR)] have been suggested as susceptibility factors for lung cancer (10) (11) (12) . In general, tobacco-derived carcinogens including polycyclic aromatic hydrocarbons are metabolized by bioactivation (phase I) and detoxification (phase II) enzymes in the carcinogenic process. DNA repair capacity has been called a 'double-edged sword' in the risk of lung cancer (13) because it is involved in not only protecting the genome from cancer-causing insults such as cigarette smoke and asbestos but also that increased DNA repair may conversely lead to increase the risk of lung cancer by decreasing the apoptosis of pre-neoplastic cells. Among the classic repair genes, the ERCC1 and ERCC2 and XRCC1 have been associated with altered lung cancer susceptibilities. DNA methylation is an epigenetic event whose pattern is altered frequently in a wide range of human cancers (14) . MTHFR is believed to be involved in the process of DNA methylation itself, which has been implicated with cancer risk (15, 16) .
Recent studies showed that genetic variants of metabolizing genes are associated with increased DNA adduct levels in target lung tissue, but inconsistent results were found with non-target (blood) tissue (17) .
In this study, we aimed to investigate whether genetic polymorphisms in metabolizing genes (GSTs, NAT2, EPHX and NQO1), DNA repair genes (ERCC1, ERCC2 and XRCC1) and MTHFR genes (MTHFR C677T and A1298C) modify the association between DNA adducts in blood mononuclear cells (MNCs) and target lung tissue. This question is important as blood DNA adduct measures are commonly used in molecular epidemiology investigations of lung cancer risk (6) .
Materials and methods

Study population
This study was approved by the Committees on the Use of Human Subjects in Research at the Massachusetts General Hospital and the Harvard School of Public Health. The study population consists of lung cancer patients undergoing resection for stages I-II lung cancer at Massachusetts General Hospital in Boston, as we described previously (3, 17) . Surgically resected, visibly noninvolved lung tissue was sampled from the same lobe, distal to the tumor, in 142 patients. Among the cases, blood volumes ! 20 ml considered sufficient for DNA adduct analysis were available for 53 patients. Among the participants, non-smokers (n 5 7) were excluded. Socio-demographic factors and smoking and medical history were obtained by trained interviewers using a modified standardized American Thoracic Society respiratory questionnaire.
Genotyping
The principles and details of the genotyping assays have been described previously by our laboratory (18) (19) (20) . All of the genetic polymorphisms were analyzed using a multiplex polymerase chain reaction-restriction fragment length polymorphism technique. The NAT2 genotypes were categorized into rapid and slow acetylators as described previously (17, 19) . The EPHX was labeled into two different enzyme activity groups (low and high) according to the gene polymorphisms in EH3 and EH4 (20) . For quality control, a random 5% of the samples were repeated to validate genotyping procedures.
Analysis of DNA adducts
We used previously reported data on DNA adducts in lung and blood MNCs samples determined by the 32 P-postlabeling assay (2,3). These DNA adducts are considered primarily to represent tobacco-derived aromatic hydrophobic adducts, mainly polycyclic aromatic hydrocarbon-DNA adducts (2) . As in prior studies, total relative DNA adducts were measured in the diagonal reactive zone plus discrete adducts in prior studies. The DNA adducts level was expressed as relative adduct level (2, 3) . Each sample was repeated at least twice as a validation analysis and average adduct levels were obtained from the combination of all experiments of the relative adduct levels. The coefficient of variation for the repeated measurements was 14% for the positive control sample of DNA containing benzo[a]pyrene diol-epoxide-labeled deoxyguanosine (3).
Abbreviations: ERCC1, excision repair cross complementation group 1; ERCC2, excision repair cross complementation group 2; EPHX, encoding microsomal epoxide hydrolase; GST, glutathione S-transferases; MNC, mononuclear cell; MTHFR, methylenetetrahydrofolate reductase; NAT2, N-acetyltransferase-2; NQO1, NAD(P)H quinone oxidoreductase 1; XRCC1, X-ray repair cross complementing group 1.
Ó The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com For studies that dichotomized DNA adduct levels, they report the OR or IRR (with 95% confidence interval in parentheses) comparing high (greater than the median level) versus low (lower than the median level) adduct levels.
Statistical analysis
Dependent and independent variables, DNA adduct levels in lung and blood MNCs per 10 10 nucleotides, respectively, were transformed using natural logarithms to improve normality. All genotyping variables were treated as dichotomous variables. Pearson correlation coefficient was used for linear relationship between DNA adduct in lung and blood MNCs by each genotype. Linear regressions were applied to assess the ability of DNA adducts in blood MNCs to predict lung adduct and their modification by genetic polymorphic genes. To test the potential modifying effects of each genotype, a cross-product term for interaction with blood DNA adducts was included along with the main effects. The regression coefficients (b) represent changes in log DNA adducts in lung (10 10 nucleotides) when the log DNA adducts in blood MNCs (10 10 nucleotides) changes 1 U. To account for the multiple comparisons across the genome, q values were calculated using the false discovery rate (21) . All statistical analyses were performed using SAS version 9.2 (SAS Institute, Carry, NC).
Results
Details of demographic and clinical data were provided in another reports (3, 17) , as shown in Table II . The geometric mean and the correlation coefficient (r) and the regression coefficient (b) between DNA adduct in lung and blood MNC by each genotype were shown in Table III . The geometric mean of DNA adduct levels were 271.1 adducts per 10 10 nucleotides in lung tissue and 100.2 adducts per 10 10 nucleotides in MNC samples. We confirmed the previous finding by our group (3) that the DNA adducts levels in blood MNC were significantly correlated with DNA adducts levels in lung tissue (r 5 0.76, P , 0.0001). However, the correlation coefficient between DNA adduct in lung and blood MNC differed by each genotype. The correlation coefficient with the variant genotype of the slow NAT2 acetylator, NQO1, ERCC1 (C118T) and MTHFR genes was somewhat lower than those with the wild-type alleles, whereas opposite directions were found with the variant genotype of DNA repair genes, ERCC1 (8092A), ERCC2 (Asp312Asn) and XRCC1 (Arg399Gln). The magnitude of correlations and the difference in the regression coefficients (beta) of DNA adducts in blood MNC and lung according to each genotypes were given in Figure 1 and Table III . The regression coefficient (b) of log DNA adducts in blood MNCs for log DNA adducts in lung was 0.88 (P , 0.001). The correlation between DNA adducts in lung and blood was not considerably changed by the GSTs polymorphisms. However, significant differences in regression lines were found by phase II genes [NAT2 (1.51 for rapid versus 0.76 for slow, P 5 0.022)] and DNA repair genes [ERCC1 C118T (1.25 for CC versus 0.66 for CTþTT, P 5 0.014), ERCC2 (0.47 for Regression coefficient between DNA adducts levels in lung and blood MNC.
Genetic modifiers of carcinogen DNA damage GG versus 1.23 for GAþAA, P 5 0.003) and XRCC1 (0.58 for GG versus 1.06 for GAþAA, P 5 0.025)]. Marginal differences were found by NQO1 (0.99 for CC versus 0.59 for CTþTT, P 5 0.097), EPHX (0.51 for high versus 0.98 for low, P 5 0.072) and ERCC1 C8092A (0.66 for CC versus 1.06 for CAþAA, P 5 0.077). Significant modification was also found by MTHFR genes [C677T (0.59 for CTþTT versus 1.27 for CC, P 5 0.005) and A1298C (0.58 for ACþCC versus 1.22 for AA, P 5 0.005)]. Consistent results were found after accounting for multiple comparisons using false discovery rate criteria (data not shown).
Discussion
In this study, we found that genetic polymorphisms of metabolizing genes (NAT2, EPHX and NQO1), DNA repair genes involved in nucleotide (ERCC1 and ERCC2) and base excision repair (XRCC1) as well as epigenetic silencing of MTHFR (C677T and A1298C) modify the relation between carcinogen DNA adducts in target (lung) and non-target (blood) tissues. Specifically, the slopes of the regression line of DNA adducts in lung and blood MNCs were significantly lower according to individual genetic variants of NAT2, EPHX, NQO1 and MTHFR genes than among the referents, whereas higher slopes were found by the variants of each DNA repair gene.
The underlying mechanisms for modifying effects of genetic factors are unclear, but our data may be explained by several likely mechanisms. Blood and lung tissues have different metabolic gene expression and activities (22) . These differences can occur even within different compartments in the same lung (23) . In addition, experimental studies indicate that DNA adduct formation is probably to be linear dose-response relationship at low doses, whereas saturation of DNA adduct formation was found at high doses with the existence of a threshold (24, 25) . Since the common alleles in phase II enzymes reduce the metabolites and products derived from phase I metabolism, eventually these common alleles could increase the capacity to metabolize the load of carcinogen from respiratory system. Therefore, the slope between DNA adducts in blood and lung could be steeper in persons with the common, wild-type alleles versus the variant alleles in phase II genes. Our data indicate that the ability of DNA adducts in blood MNCs to predict lung adducts is modified by the individual DNA repair enzymes. In particular, the slope between DNA adduct in blood and lung was significantly higher among individuals with variant genotypes of ERCC2 (Asp312Asn) and XRCC1 (Arg399Gln) than among those with wild-type genotypes, whereas opposite directions were also found with the variant genotypes of ERCC1 (C118T). The common alleles of DNA repair gene may prevent programmed cell death, but paradoxically increase the M.-S. Lee et al. accumulation of DNA adducts in the cell. Therefore, common alleles of DNA repair genes could decrease the slope between DNA adducts in blood and lung. The direction of effect on correlation between adducts in blood and lung varied for polymorphisms in the same gene, such as the two ERCC1. The reason for this is unclear, but the predictive role of two ERCC1 polymorphisms, C8092A and C118T, in the survival of lung cancer patients has been inconsistent (26) . Additional studies are warranted to further confirm these findings and to clarify underlying molecular mechanisms. The slope of DNA adducts in blood and lung differed significantly by virtue of polymorphisms in MTHFR genes (C677T and A1298C). The reason for involvement of MTHFR genes remains unclear, but DNA methylation of tissuedependent profiling can be hypothesized. Experimental studies showed that the effect of MTHFR genotype on methylation capacity was tissue specific in mice and highly dependent on diet (27) . The DNA methylation profile of liver was distinct from that of kidney and spleen in mouse (28) . In addition, the MTHFR methylation levels in lung tumor were significantly higher than those in blood (29) . Common alleles in MTHFR genes reduce the DNA adduct repair formed by carcinogen exposure and increase the DNA adducts in lung tissue. Therefore, the slope between DNA adducts in lung and blood could increase among subjects with common allelic variants of MTHFR genes.
DNA adducts in the target tissue induced from cigarette smoke reflect the overall end point of DNA damage through a cascade of metabolic bioactivation and detoxification of carcinogen(s), as well as DNA repair and cell proliferation pathway (8) . DNA adducts in blood, used as surrogate for the target lung tissue, have been implicated the risk of lung cancer (6) . A number of molecular epidemiology studies have shown a strong correlation between DNA adducts in blood and target lung tissue from same individuals (2, 3, 30) . However, the association of DNA adducts in surrogate tissue has been conflicting in terms of lung cancer risk (4) (5) (6) (7) (8) (9) . Prospective, nested case-control (4-6) and case-control studies (7, 8) have found an association between the levels of DNA adducts in leukocytes and increased risk of lung cancer (summarized in Table I ). Among the reported associations, very few studies considered the role of genetic polymorphisms in the analysis (5, 8) . Cheng et al. (8) found that individuals with high DNA adduct levels in lung had a 25-fold risk of lung cancer as compared with individuals with low DNA adduct levels after adjusting for potential confounders including CYP1A1 and GSTM1. In matched case-control studies nested within the prospective Physician's Health Study, high DNA adduct levels in white blood cell predicted a 2.98-fold risk of lung cancer among current smokers (6) and this risk increased by 4.4% after controlling for the GSTM1 and GSTP1 genotypes (5). We speculate that genetic factors may probably to be reasons for inconsistent results.
The main limitation in this study was small number of samples available, as is the case in many other molecular epidemiologic studies. A larger sample size would allow confirming our findings. Further large scale studies that can combine dense genotyping with adduct information are needed to screen for other genes that modify the relation between DNA adducts in different tissues.
In conclusion, the ability of DNA adducts in blood MNCs to predict lung adducts is modified by three pathways genes involved in phase II, DNA repair and DNA methylation. These data suggest that genetic factors in specific pathways may need to be considered when assessing the association of DNA adducts using surrogate tissue in studies of lung cancer.
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